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Background 
Hydrocortisone is widely used in patients with septic shock, 
even though  a survival  benefit has  been reported only  in 
patients  who  remained  hypotensive  after  fluid  and 
vasopressor resuscitation and whose plasma cortisol levels 
did  not  rise  appropriately  after  the  administration  of 
corticotropin.      
Methods 
Objective: To evaluate the efficacy and safety of low-dose 
hydrocortisone  therapy  in  a  broad  population  of  patients 
with septic shock — in particular, patients who had had a 
response  to  a  corticotropin  test,  in  whom  a  benefit  was 
unproven. 
Design: Multi-center, prospective randomized, double-blind, 
placebo-controlled trial. 
Setting:  International  study  involving  52  intensive  care 
units. 
Subjects: 499 patients 18 years or older with the diagnosis 
of septic shock. 
Intervention: 251 patients received 50 mg of intravenous 
hydrocortisone and 248 patients received placebo every 6 
hours for 5 days; the dose was then tapered over a 6-day 
period. A short corticotropin test was performed from blood 
samples taken immediately before and 60 minutes after an 
intravenous administration of 250 mcg of cosyntropin prior 
to administration of hydrocortisone. 
Outcomes: Primary outcome was the mortality rate at 28 
days  in  patients  who  did  not  have  a  response  to 
corticotropin.  Secondary  outcomes  included  28-day 
mortality  in  corticotropin  responders  and  in  all  patients; 
length of stay; reversal of organ failure; and rates of new 
infection, hypernatremia and hyperglycemia. 
Results 
Of the 499 patients in the study, 233 (46.7%) did not have a 
response to corticotropin (125 in the hydrocortisone group 
and 108 in the placebo group). At 28 days, there was no 
significant difference in mortality between patients in the two 
study groups who did not have a response to corticotropin 
(39.2%  in  the  hydrocortisone  group  and  36.1%  in  the 
placebo group, P=0.69) or in patients who had a response 
to  corticotropin  (28.8%  in  the  hydrocortisone  group  and 
28.7% in the placebo group, P=1.00). Mortality at 28 days 
included  86  of  251  patients  in  the  hydrocortisone  group 
(34.3%)  and  78  of  248  patients  in  the  placebo  group 
(31.5%)    (P=0.51).  Shock  reversal  was  quicker  in  the 
hydrocortisone  group  compared  to  the  placebo  group. 
However,  there  were  more  episodes  of  super  infection, 
including new sepsis and septic shock in the hydrocortisone 
group. 
Conclusions 
Hydrocortisone  did  not  improve  survival  in  patients  with 
septic shock, either overall or in patients who did not have a 
response  to  corticotropin.  However,  hydrocortisone 
hastened  reversal  of  shock  in  all  study  patients. 
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Commentary 
The  use  of  corticosteroids  in  septic  shock  has  been 
extensively  studied.  Early  investigations  determined  that 
high-dose corticosteroids in septic shock are not beneficial 
and may  be  harmful [2,3]. Interest was renewed  with the 
observation  of  hypothalamic-pituitary-adrenal  axis 
dysfunction  in  patients  with  septic  shock  [4-7].  When 
defined as an increase in plasma cortisol of ≤9 mcg/dl sixty 
minutes  after  administration  of  250  mcg  corticotropin, 
relative adrenal insufficiency (RAI) occurs in approximately 
41-63% of patients with sepsis, is predictive of death [4,7-
10]  and  is  associated  with  a  blunted  response  to 
vasopressors that can be reversed by hydrocortisone [9,11]. 
Under  this  premise,  initial  studies  of  stress-dose 
corticosteroids  (200-300  mg  hydrocortisone  per  day)  in 
septic  shock  were  conducted,  demonstrating  rapid  shock 
reversal [10,12,13]. Subsequently, in a multi-center trial in 
300  patients  with  septic  shock  refractory  to  volume 
resuscitation  and  vasopressors,  Annane  and  colleagues 
found  that  the  administration  of  hydrocortisone  50  mg 
intravenously every 6 hours and fludrocortisone 50 mcg per 
day reduced 28-day mortality by 10% in patients with RAI 
[8]. At the time of publication, this was the most definitive 
trial  of  stress-dose  steroids  in  septic  shock,  greatly 
influencing intensivists and rapidly became the standard of 
care [14]. 
The Corticosteroid Therapy  of Septic Shock (CORTICUS) 
study  evaluated  the  efficacy  and  safety  of  low-dose 
hydrocortisone  therapy  in  a  broad  population  of  patients 
with  septic  shock,  including  patients  who  responded  to  a 
corticotropin test, in whom a benefit was unproven. Patients 
were enrolled if they had clinical evidence septic shock with 
onset within 72 hours of enrollment. Shock was defined by a 
systolic  blood  pressure  (SBP)  <90  mmHg  despite  fluid 
resuscitation or a vasopressor requirement for at least one 
hour. All patients underwent a corticotropin stimulation test. 
Somewhat surprisingly, the use of low-dose hydrocortisone 
had no significant effect on 28-day mortality, regardless of 
the  patients'  adrenal  responsiveness  to  corticotropin.  The 
proportion  of  patients  in  whom  reversal  of  shock  was 
achieved  was  similar  in  the  two  groups,  though  this  goal 
was  achieved  earlier  in  patients  who  received 
hydrocortisone.  New  infection,  hypernatremia  and 
hyperglycemia  occurred  more  frequently  in  the 
hydrocortisone group compared to placebo. 
CORTICUS is the largest study to date to address the role 
of  corticosteroids  in  septic  shock.  Yet,  the  study  has 
limitations,  the  most  important  of  which  is  inadequate 
power.  The  study  was  stopped  prematurely  due  to  slow 
recruitment, termination of funding, and time expiry of the 
trial drug. As such, only 500 of the intended 800 patients 
were enrolled. This, coupled with a lower control death rate 
than anticipated, resulted in the trial having less than 35% 
power  to  detect  a  relative  risk  reduction  of  20%  for  the 
primary  outcome  [15].  Selection  bias  is  another  potential 
limitation. Physicians who were convinced of the benefit of 
steroids may have been reluctant to withhold this therapy 
from their sickest patients, thereby excluding the group of 
patients that theoretically had the most to gain. The lower 
than expected mortality rate in the control group supports 
this notion. To better understand the potential influence of 
this limitation, it would have been useful for the authors to 
have  provided  information  about  the  patients  who  were 
screened but not included in the study, such as those who 
were  excluded  because  they  were  already  receiving 
corticosteroids. 
In  comparing  CORTICUS  and  the  study  by  Annane  and 
colleagues, there are important methodological differences, 
which  may  in  part  explain  their  differing  findings.  In  the 
Annane study, patients were enrolled within eight hours of 
onset of shock and were still hypotensive (SBP <90 mmHg 
for  at  least  one  hour)  despite  fluid  resuscitation  and 
vasopressor  therapy.  In  contrast,  CORTICUS  enrolled 
patients  with  evidence  of  shock  within  the  previous  72 
hours,  as  manifest  by  either  hypotension  after  fluid 
resuscitation  or  a  vasopressor  requirement  for  at  least  1 
hour. This led to a disparity in severity of illness between the 
trials, with Annane and colleagues enrolling a sicker group 
of  patients  as  measured  by  SAPS  II  scores  and  control 
group  mortality  (table).These  observations  bring  into 
question not only the issue of timing, but also whether sicker 
patients might be more likely to benefit, as was seen with 
recombinant  human  activated  protein  C  [16].  CORTICUS 
patients  more  commonly  had  post-surgical,  hospital-
acquired,  and  abdominal  infections.  Patients  with  these 
characteristics  may  respond  differently  to  steroid  therapy 
than the primarily medical sample studied by Annane and 
colleagues. Finally, the trials also employed different steroid 
treatment protocols. The Annane trial used a fixed dose of 
hydrocortisone  along  with  fludrocortisone  for  a  total  of  7 
days;  whereas  in  CORTICUS,  a  tapering  dose  of 
hydrocortisone  (without  fludrocortisone)  for  a  total  of  11 
days  was  used. Whether  the  use  of  mineralocorticoids  is 
important or a shorter, fixed dose regimen could have made 
a difference remain important and unanswered questions. 
 Characteristic  Annane  CORTICUS 
SAPS  II  mean 
(placebo/treatment) 
57/60  49/50 
Control group mortality  61%  32% 
Corticotropin non-responders  77%  47% 
Admission category - medical  60%  35% 
Hospital-acquired infection   21%  47% 
Post-surgical infection  16%  61% 
Abdominal infection  16%  49% 
Table  1:  Comparison  of  patient  characteristics  in 
CORTICUS and the study by Annane and colleagues. 
 
There  are  two  additional  studies  addressing  the  use  of 
corticosteroids  in  septic  shock  that  should  be  mentioned. 
The  Combination  of  Corticotherapy  and  Intensive  Insulin 
Therapy for Septic Shock (COIITSS) study is completed, but 
not yet published [17]. This study used a factorial design in 
508  adults  with  septic  shock  to  simultaneously  compare 
hydrocortisone  alone  versus  hydrocortisone  plus 
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conventional  glucose  control.  The  other  study,  Activated 
Protein  C  and  Corticosteroids  for  Human  Septic  Shock 
(APROCCHS),  is  ongoing  [18].  APROCCHS  aims  to 
compare  the  efficacy  and  safety  of  recombinant  human 
activated protein C to that of low dose of corticosteroids and 
to investigate the interaction between these drugs in 1280 
adults with septic shock. 
Recommendation 
Pending  results  of  adequately  powered  studies,  it  would 
seem appropriate to reserve corticosteroids for patients with 
septic shock whose blood pressure is poorly responsive to 
fluid resuscitation and vasopressor therapy [19]. There are 
no  data  defining  what  constitutes  adequate  fluid 
resuscitation  or  what  level  of  vasopressor support  should 
trigger  initiation  of  corticosteroids.  Furthermore,  the 
corticotropin  stimulation  should  not  be  used  to  determine 
which  patients  should  receive  steroid  therapy  for  septic 
shock. Given the potential risks of infection, hyperglycemia, 
and  myopathy,  discontinuing  corticosteroids  should  be 
considered if patients fail to respond to treatment. 
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